Roche Diagnostics showcases scientific leadership and innovation at ADLM 2025 conference
Roche Unveils Suite of New Diagnostic Solutions at ADLM 2025
At the recent Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo in Chicago, Roche Diagnostics showcased a suite of eight new diagnostic solutions, highlighting their commitment to science-driven leadership, operational simplicity, and patient-centric partnership.
The new offerings include the cobas® Mass Spec solution, a future end-to-end clinical mass spectrometry platform designed for seamless integration into routine labs. Another innovation is the cobas® pure integrated solutions, which combine clinical chemistry, immunoassay, and ion-selective electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs.
One of the most significant announcements was the cobas® liat system, a point-of-care PCR system delivering results within 20 minutes for an expanding menu of CLIA-waived respiratory and sexual health assays. This system brings gold-standard PCR technology to the point of care, providing quick and accurate results where they are needed most.
Other key innovations showcased include the CCM Vertical system, a modular, space-efficient system that integrates with existing cobas connection modules to maximize lab space. There's also the cobas® eplex system, a rapid syndromic molecular diagnostic tool for respiratory and bloodstream infections, covering the entire testing process from order to report.
Roche also unveiled updates to their molecular diagnostic platforms, with the cobas® 6800/8800 Systems v2 boasting improved usability, workflow efficiency, and new software updates based on customer feedback. The LightCycler® PRO qPCR system offers enhanced accuracy and flexibility for research and clinical labs.
In addition, Roche presented the VENTANA® DP 600 slide scanner, a digital pathology device that scans stained tissue slides, digitizing and compressing images for storage and review.
Roche's presence at ADLM also emphasized their commitment to advancing diagnostics through AI-powered digital transformation, improved laboratory efficiency, and strengthening healthcare partnerships via their navify® digital solutions platform.
Roche's future cobas® Mass Spec solution is designed to be a total end-to-end solution for clinical mass spectrometry testing, aiming to deliver deeper insights, faster support, and better outcomes. The company is also committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Roche partners with many stakeholders and combines its strengths in Diagnostics and Pharma with data insights from the clinical practice. The company is a pioneer in personalized healthcare and aims to further transform how healthcare is delivered.
At ADLM, Roche will present its full array of navify® digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. They will also host two expert-led workshops: "Cardiovascular Risk Assessment and Lipoprotein(a): Closing Gaps in ASCVD Prevention" and "Innovations in Cervical-Cancer Screening and Diagnosis".
Founded in Basel, Switzerland in 1896, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. Sustainability has been an integral part of Roche's business for over 125 years. For more information about Roche's participation at ADLM 2025, visit ADLM.roche.com. However, note that the cobas® 6800/8800 System Software 2.0 and new models for the system are not yet available in the U.S.
[1] Roche Diagnostics unveils suite of new diagnostic solutions at ADLM 2025
[3] Roche Diagnostics showcases diagnostics leadership at ADLM 2025
[5] Roche Diagnostics emphasizes commitment to advancing diagnostics at ADLM 2025
- The suite of new diagnostic solutions unveiled by Roche Diagnostics at ADLM 2025 includes the cobas® Mass Spec solution, designed for seamless integration into routine labs, emphasizing their investment in health-and-wellness technology and medical-conditions research.
- At ADLM 2025, Roche Diagnostics highlighted their commitment to science-driven advancements in diagnostics, as demonstrated in their new offerings such as the cobas® liat system, which offers quick and accurate results for various medical-conditions tests, benefiting both healthcare professionals and patients.
